Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Altman Z-score
Incyte Corporation's Altman Z-score for fiscal 2025 is 8.57, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 8.57 | 3.38 |
| FY2024 | 5.19 | (1.58) |
| FY2023 | 6.77 | (1.91) |
| FY2022 | 8.68 | (0.99) |
| FY2021 | 9.67 | (2.72) |
| FY2020 | 12.39 | (2.32) |
| FY2019 | 14.71 | 2.94 |
| FY2018 | 11.77 | (5.22) |
| FY2017 | 17.00 | 7.66 |
| FY2016 | 9.33 | (3.88) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.50 | — | 0.61 | |
| Retained earnings / total assets | 0.03 | — | 0.04 | |
| EBIT / total assets | 0.22 | — | 0.72 | |
| Market value of equity / total liabilities | 10.77 | — | 6.46 | |
| Sales / total assets | 0.74 | — | 0.74 | |
| Altman Z-score | Safe zone | 8.57 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 7.90 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 28.3× |
| EXEL Exelixis, Inc. compare | 12.7× |
| INSM Insmed, Inc. compare | 9.3× |
| INCY Incyte Corporation | 8.6× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 7.3× |
| GMAB Genmab A/S Sponsored ADR compare | 2.8× |
| ASND Ascendis Pharma A/S compare | 2.0× |
| RPRX Royalty Pharma PLC compare | 1.6× |
| BNTX BioNTech SE Sponsored ADR compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement